Stand out for this role — generate a tailored resume and cover letter in about a minute.
A*STAR's Laboratory of Systems Biology & Data Analytics is seeking a Post-Doctoral Fellow to drive a STDR-funded project on genome-engineered hiPSCs for cell therapy. You will lead hands-on experiments, handle data, and collaborate with industrial partners BetaLife and IMCB teams to translate findings toward clinical applications.
The successful candidate will have extensive experience with stem cell culture, genome editing and nucleic acid techniques, and will work in a dynamic,
We are a team headed by Dr Matias I Autio, Senior Scientist in the Laboratory of Systems Biology & Data Analytics.
We are embarking on an STDR funded proof‑of‑concept project to establish a method for generating genome‑engineered induced pluripotent stem cells for use in cell therapy. The project is closely linked with industrial partners and the aim is to translate the results eventually into the clinic.
We are looking for a Post‑Doctoral Fellow to drive the research activities for the duration of the project.
The next generation of cell therapies will utilize targeted integration of therapeutic payload transgenes into the genome of the cells. For disease indications where the engineered therapeutic cells require large or multiple payload transgenes, successful transgene integration poses drastic challenges. These challenges include, for example efficiency, random integration of transgenes and off‑target effects. To address the above challenges, we have identified a shortlist of human genomic safe harbours (GSH), safe sites for transgene integration in the genome, and validated a selection of them in pluripotent stem cells and their differentiated progeny. We have also built a suite of non‑viral tools for precise targeting of our GSH which offer un‑paralleled transgene integration efficiency in human pluripotent stem cells (PSC). Together, the validated GSH and a toolbox for their targeted transgene integration offer a platform for engineering human induced PSC (hiPSCs) with large modular therapeutic payloads for multiple different disease indications. One application for our technology would be the generation of a series of hypoimmunogenic hiPSC lines that can be used as the basis for allogeneic cell therapy. Upon knockout of HLA genes, the edited hiPSCs can be further modified by integrating immune modulatory genes at the validated GSH sites to improve immune tolerance against different allogeneic immune attack pathways. Subsequently, hiPSCs can be differentiated into pancreatic islet cells and transplanted in Type 1 diabetes (T1D) patients to restore endogenous insulin production potentially without the need for routine immunosuppressants. This strategy is essential for overcoming the immunogenicity of transplanted cells and providing greater safety and accessibility to patients in need.
This project is run in close collaboration with A/Prod Adrian Teo’s team from IMCB, as well as our industrial collaborator BetaLife Pte Ltd.